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Abstract We have derived skeletal muscle cell lines from wild-
type (wt) and insulin receptor (IR) knockout mice to unravel the
metabolic potential of IGF-1 receptor (IGF-1R). Both wt and
IR^/^ myoblasts differentiated into myotubes with similar
patterns of expression of muscle-specific genes such as MyoD,
myogenin and MLC1A indicating that IR is not required for this
process. Binding of 125I-IGF-1 on wt and IR^/^ myotubes was
similar showing that IGF-1R was not upregulated in the absence
of IR. Stimulation of IR^/^ myotubes with IGF-1 (10310 to 1037
M) increased glucose uptake and incorporation into glycogen,
induced IRS-1 phosphorylation and activated PI 3-kinase and
MAP kinase, two enzymes of major signaling pathways. These
effects were comparable to those obtained with wt myotubes
using insulin or IGF-1 or with IR^/^ myotubes using insulin at
higher concentrations. This study provides a direct evidence that
IGF-1R can represent an alternative receptor for metabolic
signaling in muscle cells. ß 2001 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
The biological e¡ects of insulin and insulin-like growth fac-
tors (IGFs) are mediated by the insulin receptor (IR) and the
IGF-1 receptor (IGF-1R) which are very similar heterotetra-
meric K2L2 receptor tyrosine kinases [1]. Studies concerning
speci¢city and redundancy between IR and IGF-1R in vivo
are hampered for a variety of reasons. The two receptors,
present on the surface of most of the cells, activate common
signaling pathways [2,3] and can bind the heterologous li-
gands. Moreover, some biological e¡ects might be achieved
through IR/IGF-1R hybrid receptors [4]. Mutant mice carry-
ing a null mutation in the genes encoding IR [5,6] or IGF-1R
[7] and cell systems derived from these mutants [8^10] repre-
sent unique tools for dissecting the speci¢c contributions of
IR and IGF-1R, respectively, in cell growth, di¡erentiation
and metabolism.
Although a number of studies have reported that IGF-1 can
mimic certain metabolic actions of insulin ([11] and references
therein), there has been considerable controversy as to
whether the metabolic e¡ects of IGF-1 are exerted through
IR or IGF-1R or through IR/IGF-1R hybrid receptors [12^
14]. This issue was readdressed more recently with IR knock-
out mice. These mutants developed a severe diabetic ketoaci-
dosis and hyperlipidemia associated with hepatic steatosis,
and died within a week after birth [5,6]. Although IGF-1R
cannot fully substitute for the absence of IR, there is now
some evidence that certain metabolic e¡ects could be achieved
through IGF-1R in IR3=3 mice. First, intraperitoneal injec-
tion of IGF-1 in IR3=3 mice promptly reduced their hyper-
glycemia although plasma fatty acid levels were una¡ected
[15]. It was shown that IGF-1 treatment of IR3=3 mice re-
sulted in activation of phosphatidylinositol 3-kinase (PI 3-ki-
nase) in skeletal muscle and liver and downregulation of phos-
phoenolpyruvate carboxykinase (PEPCK) gene expression in
the liver indicating that the e¡ect of IGF-1 in lowering blood
glucose level was presumably due to the stimulation of periph-
eral glucose utilization and inhibition of hepatic gluconeogen-
esis, although these were not directly measured. Second, since
IR3=3 mice become hyperinsulinemic, one could wonder
whether insulin, at high concentrations, could exert some of
its e¡ects through IGF-1R. This assumption was supported
by the fact that double knockout mice for Ins1 and Ins2 de-
velop the same metabolic disorders as IR3=3 mice but more
rapidly and die sooner [16].
In skeletal muscle, a major target tissue for the metabolic
action of insulin in vivo, both IR and IGF-1R are present in
di¡erentiated muscle cells [17,18]. To further assess IGF-1R as
an alternative receptor to IR for metabolic signaling, we have
derived muscle cell lines from wild-type (wt) and IR3=3 mice.
We ¢rst examined the ability of wt and IR3=3 myoblasts to
di¡erentiate into myotubes in culture. The results obtained
indicated that IR is not required for this process. We could
therefore perform a comparative analysis of the ability of
IGF-1 and insulin to lead to metabolic e¡ects and to activate
signaling pathways in wt and IR3=3 myotubes.
2. Materials and methods
2.1. Cell cultures
Skeletal muscle cell lines from wt and IR3=3 newborn mice were
obtained as described [19]. Brie£y, posterior legs freed of skin and
bones were minced and digested with trypsin and collagenase. After
centrifugation, the cells were plated onto collagen-coated dishes and
cultured in DMEM with 25 mM glucose/20% fetal calf serum (FCS)/
2% ultroser (Biosepra). After few passages, stable muscle cell lines
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were recovered and cultured in the same medium. It was veri¢ed that
the cell line from IR3=3 mice carried a homozygous null mutation for
IR by genotype analysis of cellular DNA [6]. All experiments were
performed with cells between 20^40 passages. Con£uent myoblast
cultures di¡erentiated into myotubes upon serum starvation (2^7%
FCS) during 7^9 days.
2.2. RNA extraction and Northern blot analysis
Total RNA was extracted from cells using RNazol B (Campro).
RNA samples (10 Wg) were run on 1% formaldehyde-agarose gels
and transferred onto nylon membranes. Filters were hybridized at
65‡C with probes synthesized with cloned rat cDNA fragments spe-
ci¢c for MyoD, myogenin and MLC1A as described [20] using a
random priming kit (Amersham) and [K32P]dCTP (3000 Ci/mmol;
Amersham). The ribosomal S26 protein RNA was hybridized as in-
ternal control using a 32P-labeled probe synthesized using a cloned
cDNA fragment as indicated [20]. Following hybridization, the blots
were washed and exposed to X-ray ¢lms for autoradiography for 1^2
weeks.
2.3. 125I-IGF-1 binding assays
The binding of 125I-IGF-1 was performed as follows. Myotubes
were serum-starved for 18 h in DMEM with 5 mM glucose/0.2%
bovine serum albumin (BSA), washed and incubated in the same
medium for 2 h at 37‡C. After washing with cold PBS, myotubes
were incubated in the binding bu¡er (100 mM HEPES pH 7.6,
100 M NaCl, 5 mM KCl, 1.3 mM MgSO4, 15 mM sodium acetate,
5 mM glucose, 1% BSA) containing 125I-IGF-1 (25 000 cpm; 2000
Ci/mmol; Amersham). For non-speci¢c binding, cold IGF-1 (GroPep)
was added at 1 WM. After 4 h at 15‡C, myotubes were washed with
cold PBS and solubilized in 0.05% SDS/PBS at 37‡C for 30 min and
cell lysates were counted in a gamma counter. Protein concentrations
were determined using the Bio-Rad reagent and BSA as standard.
2.4. 2-Deoxyglucose uptake
Myotubes were serum-starved for 18 h in DMEM with 5.5 mM
glucose/0.1% BSA and then incubated for 2 h at 37‡C in DMEM
without glucose/25 mM HEPES. The myotubes were washed with
PBS, stimulated with IGF-1 or insulin (Sigma) for 30 min at 37‡C
in HEPES bu¡er (50 mM HEPES pH 7.4, 140 mM NaCl, 1.85 mM
CaCl2, 1.3 mM MgSO4, 4.8 mM KCl)/0.1% BSA/0.1 mM 2-deoxy-
glucose and further incubated with 0.1 mM 2-deoxyglucose and
0.5 WCi of 2-deoxy-D-[2,6-3H]glucose (25^55 Ci/mmol; Amersham)
for 10 min at 37‡C. Myotubes were washed and lysed as described
[9] and the radioactivity was counted.
2.5. Glucose incorporation into glycogen
Glucose incorporation into glycogen was performed essentially as
described [21]. After serum starvation as above, myotubes were incu-
bated for 3 h at 37‡C in DMEM/2.5 mM glucose/0.1% BSA/25 mM
HEPES pH 7.6. After washing with PBS and stimulation with IGF-1
or insulin for 30 min at 37‡C, 1 WCi of D-[U-14C]glucose (250
mCi/mmol; Amersham) was added for 90 min. Myotubes were
washed with cold PBS and solubilized with 30% KOH. After boiling
the samples, glycogen was precipitated with 95% ethanol at 4‡C and
recovered on Whatman GFB ¢lters which were counted for radio-
activity.
2.6. IRS-1 phosphorylation
Myotubes were serum-starved for 18 h in DMEM/0.2% BSA,
stimulated with IGF-1 or insulin for 3 min at 37‡C and solubilized
in the lysis bu¡er as described [9]. Lysates (0.3 mg) were incubated
with anti-insulin receptor substrate-1 (IRS-1) rabbit polyclonal anti-
bodies (Upstate Biotechnology) and protein A-Sepharose (Pharmacia)
was added. The immunoprecipitates were run on 7.5% SDS^PAGE
following electrotransfer onto nitrocellulose membranes (Schleicher
and Schuell). Filters were blocked and ¢rst incubated with anti-IRS-
1 rabbit polyclonal antibodies then with anti-rabbit horseradish per-
oxidase conjugated antibody (DAKO). Blots were revealed using the
enhance chemiluminescence (ECL) detection system (Amersham) and
exposed to X-ray ¢lms for 1^5 min. Membranes were then stripped
and reblotted with anti-phosphotyrosine mouse monoclonal antibody
(PY99; Santa Cruz).
2.7. Assay of PI 3-kinase activity
PI 3-kinase activity was measured as described [22]. Brie£y, myo-
tubes were serum-starved as above and stimulated with IGF-1 or
insulin for 10 min at 37‡C and solubilized in lysis bu¡er. Lysates
(0.5 mg) were incubated with mouse monoclonal anti-phosphotyrosine
antibody (PY20; Transduction Laboratories) and protein A-Sephar-
ose. The pellets were washed and resuspended in 30 Wl of the reaction
bu¡er (20 mM HEPES pH 7.5, 0.4 mM EDTA and 0.4 mM
Na4P2O7) and 10 Wl of L-K-phosphatidylinositol (10 mg/ml in 5 mM
HEPES pH 7.5, Sigma). The reaction was started by adding 10 Wl of a
mixture containing 10 WCi of [Q-32P]ATP (4500 Ci/mmol; ICN),
50 mM MgCl2, 0.25 mM ATP, 14 mM HEPES pH 7.5, 0.28 mM
EDTA and 0.28 mM Na4P2O7 and shaken at room temperature for
15 min. The samples were processed and analyzed by thin layer chro-
matography as described [9] and the plates were exposed to X-ray
¢lms for 48 h.
2.8. Assay of MAP kinase phosphorylation
To examine the activation of the mitogen-activated protein kinase
(MAP kinase), myotubes were serum-starved as above, stimulated
with IGF-1 or insulin for 10 min at 37‡C and solubilized in lysis
bu¡er. Protein extracts (0.3 mg) were run on 12% SDS^PAGE and
electrotransferred onto nitrocellulose membranes. Membranes were
blocked and incubated with anti-active MAP kinase (p42/p44) speci¢c
rabbit polyclonal antibodies (Promega) and then treated with an anti-
rabbit horseradish peroxidase conjugated secondary antibody. The
¢lters were revealed using the ECL detection system and exposed to
X-ray ¢lms for 2^5 min.
Fig. 1. Di¡erentiation of wt and IR3=3 muscle cell lines in culture.
A: Morphology of wt and IR3=3 muscle cells before and after fu-
sion into myotubes. Magni¢cations are U94 for myoblasts and
U188 for myotubes. B: Expression of muscle-speci¢c genes during
di¡erentiation of wt and IR3=3 cells. Subcon£uent myoblasts (day
0) were grown to con£uence and induced to di¡erentiate by serum
starvation at day 3. Total RNA was extracted and analyzed by
Northern blot hybridization using 32P-labeled probes as described in
Section 2.
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3. Results and discussion
It is now well established that IGF-1R plays an important
role in cellular growth and di¡erentiation [7]. However, the
question as to whether IGF-1R has a full or limited metabolic
potential in muscle, liver or fat tissue as compared to that of
IR is still a matter of debate. In this work, we have derived
muscle cell lines from wt and IR3=3 mice to examine possible
redundancy between IR and IGF-1R for metabolic action in
muscle cells.
3.1. Di¡erentiation of myoblasts into myotubes in the absence
of IR
Both wt and IR3=3 muscle cells presented the same aspect
at the myoblast stage and were able to di¡erentiate to form
morphologically similar myotubes (Fig. 1A). Moreover, Tro-
ponin T, a marker speci¢c for di¡erentiated muscle cells,
could be detected in wt as well as in IR3=3 myotubes by
immunocytochemistry using an anti-Troponin T antibody
(not shown). Since muscle cell di¡erentiation is accompanied
by temporally regulated expression of genes encoding myo-
genic factors or muscle-speci¢c structural proteins, we also
examined the expression of such genes during the conversion
of myoblasts into myotubes by Northern blot analysis. The
expression of the MyoD gene appeared to be higher in IR3=3
proliferating myoblasts as compared to wt myoblasts. Never-
theless, its expression decreased during the di¡erentiation pro-
cess for both lines (Fig. 1B). After inducing the di¡erentiation
of con£uent myoblast cultures by serum starvation, the ex-
pression of genes for myogenin and MLC1A was increased
within 24 h for both wt and IR3=3 cells and was maintained
at high level throughout the di¡erentiation process (Fig. 1B).
All these observations indicate that normal muscle cell di¡er-
entiation can take place in the absence of IR.
To examine whether there exists any compensatory upreg-
ulation of IGF-1R in the absence of IR, we performed 125I-
IGF-1 binding experiments. Fig. 2 shows that 125I-IGF-1
binding was very similar for both wt and IR3=3 myotubes
precluding any IGF-1R upregulation in IR3=3 myotubes.
3.2. Metabolic action of IGF-1/insulin in IR3=3 and wt
myotubes
The ability of IGF-1 or insulin to stimulate glucose uptake
and glucose incorporation into glycogen was measured in
IR3=3 and wt myotubes. Glucose transport was measured
using the non-metabolized [3H]-2-deoxyglucose analog. As
shown in Fig. 3A, IGF-1 was able to stimulate glucose uptake
in IR3=3 myotubes and the dose^response curve was very
similar to those obtained for wt myotubes with insulin or
IGF-1. Insulin was also able to stimulate glucose uptake in
IR3=3 myotubes but the dose^response curve was shifted to
the right due to the lower a⁄nity of insulin for IGF-1R. For
both wt and IR3=3 myotubes, the maximal value for IGF-1
stimulated glucose uptake was comparable to that obtained at
maximal insulin concentration.
Glucose incorporation into glycogen was measured using
Fig. 2. Binding of 125I-IGF-1 on wt and IR3=3 myotubes. Non-spe-
ci¢c binding corresponds to the values obtained in the presence of
an excess of cold IGF-1. For details see Section 2. The results are
means þ S.E.M. of three separate experiments.
Fig. 3. Metabolic e¡ects in wt and IR3=3 myotubes stimulated by
IGF-1 or insulin. A: Stimulation of glucose uptake. Cells were se-
rum-starved, incubated in DMEM without glucose and stimulated
with IGF-1 or insulin prior to incubation with [3H]-2-deoxyglucose.
The cells were washed, dissolved and the radioactivity was counted.
A blank value obtained with unstimulated cells was subtracted. All
data are means þ S.E.M. of 10 independent experiments. B: Stimula-
tion of glucose incorporation into glycogen. Cells were serum-
starved and stimulated with IGF-1 or insulin. After incubation with
[14C]glucose, cells were washed and solubilized. After boiling, glyco-
gen was precipitated and recovered on ¢lters which were counted
for radioactivity. A blank value obtained with unstimulated cells
was subtracted. All data are means þ S.E.M. of 10 independent ex-
periments.
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[14C]glucose. As shown in Fig. 3B, IGF-1 could stimulate
glucose incorporation into glycogen in IR3=3 myotubes and
the dose^response curve was very close to those obtained for
wt myotubes with insulin or IGF-1. Again, glucose incorpo-
ration into glycogen in IR3=3 myotubes was stimulated by
insulin but the dose^response curve was shifted to the right
as in the case of glucose uptake. The plateau values with IGF-
1 or insulin for both lines were comparable.
These results indicate that IGF-1R can lead to metabolic
e¡ects in di¡erentiated muscle cells with an e⁄ciency that is
comparable to that of IR. Moreover, insulin, at higher con-
centrations, could lead to metabolic e¡ects through IGF-1R.
3.3. Signaling pathways activated by IGF-1/insulin in IR3=3
and wt myotubes
The mechanisms of signal transduction by IR and IGF-1R
consist in tyrosine phosphorylation of intermediate docking
proteins such as IRS-1, -2, -3 and -4 which subsequently re-
cruit various e¡ector proteins. This, in turn, results in the
activation of signaling pathways such as the PI 3-kinase or
the MAP kinase pathways [3]. Since IRS-1 appears to be the
predominant signaling intermediate in muscle cells [23], we
examined IRS-1 phosphorylation as well as PI 3-kinase and
MAP kinase activation in IR3=3 and wt myotubes in response
to IGF-1 or insulin.
To measure IRS-1 phosphorylation, lysates from myotubes
stimulated with IGF-1 or insulin were immunoprecipitated
with anti-IRS-1 antibodies and analyzed by Western blotting
using anti-IRS-1 or anti-phosphotyrosine antibodies. Fig. 4A
shows that both IGF-1 and insulin can induce IRS-1 phos-
phorylation in wt as well as in IR3=3 myotubes. As expected,
IRS-1 phosphorylation in IR3=3 myotubes by insulin required
higher concentrations. Attempts to detect IRS-2 phosphory-
lation in wt or IR3=3 myotubes in response to IGF-1 or
insulin were not successful.
To examine PI 3-kinase activation, lysates from myotubes
stimulated with IGF-1 or insulin were immunoprecipitated
using anti-phosphotyrosine antibodies. The PI 3-kinase activ-
ity in immunoprecipitates was measured by phosphorylation
of phosphoinositols in the presence of [Q-32P]ATP and analyz-
ing the products by chromatography. The autoradiograms
presented in Fig. 4B show that PI 3-kinase was activated in
IR3=3 and wt myotubes by IGF-1 or insulin. Again, activa-
tion of PI 3-kinase by insulin in IR3=3 myotubes was ob-
served with higher concentrations. Interestingly, PI 3-kinase
activation in wt myotubes was found to be more e⁄cient with
IGF-1 than with insulin.
Finally, stimulation of MAP kinase in IR3=3 and wt myo-
tubes in response to IGF-1 or insulin was examined in cell
lysates by Western immunoblotting using an anti-active MAP
kinase antibody which speci¢cally recognizes phosphorylated
MAP kinase (p42/p44). As shown in Fig. 4C, MAP kinase
C
Fig. 4. Activation of signaling pathways in wt and IR3=3 myotubes
stimulated by IGF-1 or insulin. A: Induction of IRS-1 phosphoryla-
tion. Cell lysates from wt and IR3=3 myotubes stimulated with
IGF-1 or insulin were immunoprecipitated with anti-IRS-1 antibod-
ies and immunocomplexes were analyzed by Western blotting using
anti-IRS-1 antibodies. The ¢lters were then stripped and reblotted
with anti-phosphotyrosine (PY) antibodies. Blots were revealed us-
ing the ECL detection system. B: Stimulation of PI 3-kinase activ-
ity. Cell lysates from wt and IR3=3 myotubes stimulated with IGF-
1 or insulin were immunoprecipitated with anti-PY antibodies and
PI 3-kinase activity was measured by phosphorylation of phospho-
lipids in the presence of [Q-32P]ATP. The products were analyzed by
thin layer chromatography and the autoradiogram is presented.
C: Activation of MAP kinase. Cell lysates from wt and IR3=3 myo-
tubes stimulated with IGF-1 or insulin were run on 12% SDS^
PAGE and transferred onto nitrocellulose ¢lters. Immunoblotting
was performed using an anti-active MAP kinase antibody. Blots
were revealed using the ECL detection system. ns: non-stimulated.
These results are representative of two separate experiments for
IRS-1 phosphorylation and three independent experiments for PI 3-
kinase and MAP kinase assays.
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was activated in wt and IR3=3 myotubes stimulated with in-
sulin or IGF-1, although basal MAP kinase activity was not
completely suppressed in serum-starved cells. Higher insulin
concentrations were required for MAP kinase activation in
IR3=3 myotubes. For both lines, phosphorylation of p42
was more pronounced than that of p44.
In conclusion, IGF-1 as well as insulin at higher concen-
tration can activate signaling pathways in IR3=3 myotubes.
These e¡ects are comparable to those obtained upon stimulat-
ing wt myotubes with insulin or IGF-1.
3.4. IGF-1R as an alternative receptor for metabolic signaling
in vivo?
The present study clearly shows that IGF-1R can represent
an alternative receptor to IR for metabolic signaling in IR3=3
myotubes in culture. Thus, IGF-1R-mediated stimulation of
glucose uptake and utilization in skeletal muscle could partly
account for the hypoglycemic e¡ects of IGF-1 injection in
IR3=3 mice [15]. Mutant mice in which muscle-speci¢c IR
knockout (MIRKO) was achieved using the Cre-loxP system
represent another unique in vivo situation to address the ques-
tion of the metabolic potential of IGF-1R [24]. MIRKO mice
were able to maintain euglycemia for several months with
normal plasma insulin. The compromised insulin signaling
in skeletal muscle can thus be perfectly compensated in these
mutants. Interestingly, MIRKO mice presented increased fat
deposits in several sites suggesting that glucose was likely
being shunted from muscle to fat tissue or liver. Since IGF-
1R was not found to be upregulated and little or no IGF-1R
or IRS-1 phosphorylation was observed in response to insulin
in the skeletal muscle of MIRKO mice, the issue of whether
IGF-1R could function as an alternative receptor to IR was
not further explored. In light of the present work, it would be
interesting to reexamine the ability of IGF-1 to lead to some
metabolic e¡ects through IGF-1R in isolated skeletal muscle
or in vivo using MIRKO mice.
The ability of IGF-1R to lead to metabolic e¡ects in the
liver was also examined recently using a hepatocyte cell line
derived from IR3=3 mice. It was shown that IGF-1R activa-
tion does not enhance glycogen synthesis and fails to inhibit
glucose production by these cells [10]. Thus, IGF-1 action
through IGF-1R in the liver probably does not contribute
much to the hypoglycemic e¡ect of IGF-1 injection into
IR3=3 mice. The conclusion that IGF-1R could not e⁄ciently
substitute for the absence of IR in the liver also emerged from
the analysis of liver-speci¢c IR knockout (LIRKO) mice
which presented dramatic insulin resistance, severe glucose
intolerance and a failure of insulin to suppress hepatic glucose
production and to regulate hepatic gene expression [23].
Finally, the question of whether metabolic signaling can be
achieved through IGF-1R in fat tissue cannot be easily ad-
dressed in IR3=3 mice since this tissue is very underdeveloped
in these mutants [25]. Further work would be required to
investigate whether the failure of IGF-1 to reduce circulating
free fatty acid levels in IR3=3 mice results from diminished fat
tissue in these mutants or re£ects a lower capacity of IGF-1R
to lead to metabolic e¡ects of IR on lipogenesis/lipolysis.
In conclusion, IGF-1R could represent an alternative recep-
tor to IR for metabolic signaling at least in the skeletal
muscle. However, it appears from all the recent studies per-
formed using global and/or tissue-speci¢c knockout of genes
encoding IR or insulin that the metabolic e¡ects through
IGF-1R, in vivo, would be achieved only under certain patho-
physiological conditions in which the ligands, IGFs or insulin,
become available in excess.
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